Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Healthtrust
Baxter
Citi
Covington
Johnson and Johnson
Fish and Richardson
AstraZeneca
UBS
Accenture

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,377,916

« Back to Dashboard

Which drugs does patent 8,377,916 protect, and when does it expire?


Patent 8,377,916 protects OCALIVA and is included in one NDA.

This patent has fourteen patent family members in eleven countries.

Summary for Patent: 8,377,916

Title:Steroids as agonists for FXR
Abstract: The invention relates to compounds of formula (I): ##STR00001## wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
Inventor(s): Pellicciari; Roberto (Perugia, IT)
Assignee: Intercept Pharmaceuticals, Inc. (New York, NY)
Application Number:13/288,558
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Intercept Pharms Inc
OCALIVA
obeticholic acid
TABLET;ORAL207999-001May 27, 2016RXYesNo► Subscribe► Subscribe TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
Intercept Pharms Inc
OCALIVA
obeticholic acid
TABLET;ORAL207999-002May 27, 2016RXYesYes► Subscribe► Subscribe TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,377,916

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,732,117Steroids as agonists for FXR► Subscribe
7,138,390Steroids as agonists for FXR► Subscribe
8,058,267Steroids as agonists for FXR► Subscribe
8,969,330Steroids as agonists for FXR► Subscribe
7,786,102Steroids as agonists for FXR► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,377,916

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria303399► Subscribe
Australia2002308295► Subscribe
Canada2440680► Subscribe
Germany60205891► Subscribe
Denmark1392714► Subscribe
European Patent Office1392714► Subscribe300877Netherlands► Subscribe
European Patent Office1392714► SubscribeCA 2017 00025Denmark► Subscribe
European Patent Office1392714► Subscribe122017000034Germany► Subscribe
European Patent Office1392714► SubscribeCR 2017 00025Denmark► Subscribe
Spain2248581► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Teva
Fuji
Queensland Health
Deloitte
Merck
US Department of Justice
Cantor Fitzgerald
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot